摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2E,6Z,9Z,12Z,15Z)-Octadeca-2,6,9,12,15-pentaene-1-thiol | 300553-15-5

中文名称
——
中文别名
——
英文名称
(2E,6Z,9Z,12Z,15Z)-Octadeca-2,6,9,12,15-pentaene-1-thiol
英文别名
(2E,6Z,9Z,12Z,15Z)-octadecapentaene-1-thiol
(2E,6Z,9Z,12Z,15Z)-Octadeca-2,6,9,12,15-pentaene-1-thiol化学式
CAS
300553-15-5
化学式
C18H28S
mdl
——
分子量
276.486
InChiKey
ORLHWMAIFDLKJV-IIFHDYRKSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    380.9±31.0 °C(Predicted)
  • 密度:
    0.898±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    5.9
  • 重原子数:
    19
  • 可旋转键数:
    11
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.44
  • 拓扑面积:
    1
  • 氢给体数:
    1
  • 氢受体数:
    1

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] PROCESS FOR THE PREPARATION OF A POLYUNSATURATED KETONE COMPOUND<br/>[FR] PROCÉDÉ DE PRÉPARATION D'UN COMPOSÉ CÉTONE POLYINSATURÉ
    申请人:AVEXXIN AS
    公开号:WO2016116634A1
    公开(公告)日:2016-07-28
    A process for the preparation of a polyunsaturated thiol comprising: (1) reacting a polyunsaturated alcohol in the presence of a compound of formula R2-SO2Hal wherein R2 is a C1-20 hydrocarbyl group, such an C1-10 alkyl group, to form a polyunsaturated sulphonyl ester; (2) converting the polyunsaturated sulphonyl ester to a polyunsaturated thioester by reacting with an anion of formula -SC(=O)R4 wherein R4 is a C1-20 hydrocarbyl group; (3) converting the polyunsaturated thioester to form a polyunsaturated thiol optionally in the presence of an antioxidant, e.g. using a metal carbonate. (4) reacting said polyunsaturated thiol with a compound (LG)R3COX wherein X is an electron withdrawing group and R3 is an alkylene group carrying a leaving group (LG), such as LG-CH2- forming (I) where X is an electron withdrawing group and LG is a leaving group; optionally in the presence of an antioxidant, so as to form a polyunsaturated ketone compound.
    制备多不饱和硫醇的方法包括:(1)在式R2-SO2Hal的化合物存在下,将多不饱和醇与R2为C1-20烃基的化合物(如C1-10烷基)反应,形成多不饱和磺酰酯;(2)通过与式为-SC(=O)R4的阴离子反应,将多不饱和磺酰酯转化为多不饱和硫酯;(3)在抗氧化剂的存在下,将多不饱和硫酯转化为多不饱和硫醇,例如使用金属碳酸盐;(4)将所述多不饱和硫醇与化合物(LG)R3COX反应,其中X是一个电子吸引基团,R3是携带一个离去基团(LG)的烷基链,如LG-CH2-,形成(I),其中X是一个电子吸引基团,LG是一个离去基团;在抗氧化剂的存在下,形成多不饱和酮化合物。
  • Syntheses of some polyunsaturated trifluoromethyl ketones as potential phospholipase A2 inhibitors
    作者:Anne Kristin Holmeide、Lars Skattebøl
    DOI:10.1039/b001944p
    日期:——
    Starting from (all-Z)-icosa-5,8,11,14,17-pentaenoic acid [(all-Z)-eicosa-5,8,11,14,17-pentaenoic acid, EPA] and (all-Z)-docosa-4,7,10,13,16,19-hexaenoic acid (DHA) several trifluoromethyl ketones, containing sulfur or oxygen atoms at the β-position, have been synthesized as potential inhibitors of cytosolic phospholipase A2. As part of this work EPA and DHA have been oxidatively degraded to (all-Z)-pentadeca-3,6,9,12-tetraenal and (all-Z)-octadeca-3,6,9,12,15-pentaenal, respectively, in 75% overall yields.
    从(全-Z)-5,8,11,14,17-二十碳五烯酸[(全-Z)-5,8,11,14,17-二十碳五烯酸,EPA]和(全-Z)-4,7,10,13,16,19-二十二碳六烯酸(DHA)出发,已经合成了几种含有硫或氧原子在β位的三氟甲基酮,这些化合物被认为是细胞质磷脂酶A2的潜在抑制剂。作为这项工作的一部分,EPA和DHA分别被氧化降解为(全-Z)-3,6,9,12-十五碳四烯醛和(全-Z)-3,6,9,12,15-十八碳五烯醛,总产率均为75%。
  • [EN] LIPID COMPOUNDS FOR USE IN COSMETIC PRODUCTS, AS FOOD SUPPLEMENT OR AS A MEDICAMENT<br/>[FR] COMPOSÉS LIPIDIQUES À UTILISER DANS DES PRODUITS COSMÉTIQUES, EN TANT QUE SUPPLÉMENTS ALIMENTAIRES OU EN TANT QUE MÉDICAMENTS
    申请人:PRONOVA BIOPHARMA NORGE AS
    公开号:WO2009061208A1
    公开(公告)日:2009-05-14
    The present invention relates to lipid compounds of the general formula (I): wherein • R1 is selected from a C10-C21 alkyl, a C10-C21 alkenyl having 1-6 double bonds, and a C10-C21 alkynyl having 1-6 triple bonds; • R2 and R3 are the same or different and are selected from hydrogen and a C1-C6 alkyl group; and X is selected from O, S, SO, SO2, Si or Se; • n = 1 or 3; and • P1 is selected from a hydrogen, a C10-C21 alkyl, a C10-C21 alkenyl having 1-6 double bonds, and a C10-C21 alkynyl having 1-6 triple bonds, optionally substituted; or P1 is represented by: wherein P2, P3 and P4 are selected from a hydrogen, an alkyl, alkenyl, alkynyl, optionally substituted; or P1 is a phosphonate or a phosphate ester, represented by or P1 is a sulphonate or a sulphate ester, represented by wherein P5 is a hydrogen or a C1-C6 alkyl; or a pharmaceutically acceptable salt, complex or solvate thereof. Also disclosed are pharmaceutical compositions and lipid compositions comprising such compounds, and such compounds for use as medicaments, in particular for the treatment of diseases related to the cardiovascular, metabolic and inflammatory disease area.
    本发明涉及通式(I)的脂质化合物:其中•R1选择自C10-C21烷基,具有1-6个双键的C10-C21烯基和具有1-6个三键的C10-C21炔基;•R2和R3相同或不同,选择自氢和C1-C6烷基; X选择自O,S,SO,SO2,Si或Se;•n = 1或3;•P1选择自氢,C10-C21烷基,具有1-6个双键的C10-C21烯基和具有1-6个三键的C10-C21炔基,可选择性取代;或者P1由以下式子表示:其中P2,P3和P4选择自氢,烷基,烯基,炔基,可选择性取代;或者P1是磷酸酯或磷酸酯,由以下式子表示:或P1是磺酸盐或硫酸酯,由以下式子表示:其中P5为氢或C1-C6烷基;或其药学上可接受的盐,复合物或溶剂。还披露了包括这种化合物的制药组合物和脂质组合物,以及这种化合物用于作为药物,特别是用于治疗与心血管,代谢和炎症疾病相关的疾病。
  • LIPID COMPOUNDS FOR USE IN COSMETIC PRODUCTS, AS FOOD SUPPLEMENT OR AS A MEDICAMENT
    申请人:Holmeide Anne Kristin
    公开号:US20100280109A1
    公开(公告)日:2010-11-04
    The present disclosure relates to lipid compounds of formula (I): wherein: R 1 is chosen from a C 10 -C 21 alkyl, a C 10 -C 21 alkenyl having 1-6 double bonds, and a C 10 -C 21 alkynyl having 1-6 triple bonds; R 2 and R 3 are the same or different and are chosen from hydrogen and a C 1 -C 6 alkyl; X is chosen from O, S, SO, SO 2 , Si, and Se; n=1 or 3; and P 1 is chosen from hydrogen; a C 10 -C 21 alkyl, a C 10 -C 21 alkenyl having 1-6 double bonds, a C 10 -C 21 alkynyl having 1-6 triple bonds, optionally substituted; a group of formula (II) or formula (III), wherein P 2 , P 3 , and P 4 are chosen from hydrogen, an alkyl, an alkenyl, and an alkynyl, optionally substituted; and a group of formula (IV) or formula (V), wherein P 5 is chosen from hydrogen and a C 1 -C 6 alkyl; or a pharmaceutically acceptable salt, complex, or solvate thereof. Also disclosed are pharmaceutical compositions and lipid compositions comprising such compounds, and methods of use thereof, for example in the treatment of diseases related to cardiovascular, metabolic, and inflammatory conditions.
    本公开涉及式(I)的脂质化合物:其中:R1选择自C10-C21烷基,具有1-6个双键的C10-C21烯基和具有1-6个三键的C10-C21炔基; R2和R3相同或不同,选择自氢和C1-C6烷基; X选择自O、S、SO、SO2、Si和Se; n=1或3; P1选择自氢; C10-C21烷基,具有1-6个双键的C10-C21烯基,具有1-6个三键的C10-C21炔基,可以是取代基;式(II)或式(III)中的一组,其中P2、P3和P4选择自氢,烷基,烯基和炔基,可以是取代基;以及式(IV)或式(V)中的一组,其中P5选择自氢和C1-C6烷基;或其药学上可接受的盐,复合物或溶剂化物。还公开了包含这些化合物的制药组合物和脂质组合物,以及使用它们的方法,例如治疗与心血管,代谢和炎症状况相关的疾病。
  • PROCESS FOR THE PREPARATION OF A POLYUNSATURATED KETONE COMPOUND
    申请人:AVEXXIN AS
    公开号:US20160159737A1
    公开(公告)日:2016-06-09
    The invention relates to the manufacture of certain polyunsaturated compounds employing a particular application of the Mitsonobu reaction in the presence of at least one anti-oxidant. We have found a method of making a pharmaceutically-acceptable polyunsaturated ester or thioester compound directly, which can ultimately be converted to the advantageous ketone compounds, in which unwanted oxidation and cis/trans isomerization are substantially reduced or eliminated using particular Mitsonobu chemistry.
    本发明涉及利用Mitsonobu反应的特定应用来制造某些多不饱和化合物,其中至少存在一种抗氧化剂。我们发现了一种直接制造药用多不饱和酯或硫酯化合物的方法,最终可以转化为有利的酮化合物,其中使用特定的Mitsonobu化学方法,可以大大减少或消除不必要的氧化和顺反异构化。
查看更多